John Sourbeer
Stock Analyst at UBS
(0.70)
# 3,899
Out of 4,900 analysts
36
Total ratings
36.84%
Success rate
-24.63%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $10 → $11 | $7.34 | +49.86% | 6 | Apr 1, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $25.60 | -8.20% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $27.96 | +60.97% | 4 | Feb 13, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $50 → $48 | $47.45 | +1.16% | 4 | Feb 7, 2025 | |
| WST West Pharmaceutical Services | Upgrades: Buy | $350 → $390 | $221.05 | +76.43% | 3 | Dec 12, 2024 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.44 | +38.89% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $97.15 | +49.25% | 3 | Nov 5, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $312.71 | +53.50% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $41.99 | +142.91% | 3 | Mar 1, 2024 | |
| TXG 10x Genomics | Initiates: Neutral | $50 | $12.22 | +309.17% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $270 | $145.58 | +85.47% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $131.49 | -2.65% | 2 | Jul 27, 2022 |
Cryoport
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $11
Current: $7.34
Upside: +49.86%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $25.60
Upside: -8.20%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $27.96
Upside: +60.97%
Qiagen
Feb 7, 2025
Maintains: Neutral
Price Target: $50 → $48
Current: $47.45
Upside: +1.16%
West Pharmaceutical Services
Dec 12, 2024
Upgrades: Buy
Price Target: $350 → $390
Current: $221.05
Upside: +76.43%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.44
Upside: +38.89%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $97.15
Upside: +49.25%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $312.71
Upside: +53.50%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $41.99
Upside: +142.91%
10x Genomics
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $12.22
Upside: +309.17%
Sep 7, 2022
Initiates: Buy
Price Target: $270
Current: $145.58
Upside: +85.47%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $131.49
Upside: -2.65%